Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from Prescient Therapeutics Limited ( (AU:PTX) ) is now available.
Prescient Therapeutics Limited has announced the issuance of 24 million unquoted equity securities in the form of options set to expire on January 20, 2030. These securities, issued under an employee incentive scheme, are not intended to be quoted on the ASX, indicating a strategic move to incentivize and retain key personnel within the company.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on developing targeted therapies for cancer treatment. The company is engaged in the research and development of various oncological therapeutics, aimed at offering innovative solutions in cancer care.
YTD Price Performance: -4.00%
Average Trading Volume: 654,315
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$38.66M
For a thorough assessment of PTX stock, go to TipRanks’ Stock Analysis page.
